About EMIG 2 2021-05-11T15:19:16+00:00

Who We Are

EMIG is a multi-stakeholder network and trade industry association that represents the interests of the full span of life sciences companies in the UK. Our industry Members, range from new business start-ups focused on R&D, through to well-established companies delivering a wide range of essential medicines to patients.

Our Members

EMIG has over 300 Member Companies and organisations – including Associate Members drawn from academia, patient organisations, learned societies and companies providing essential support services to the Life Sciences ecosystem. Collectively we represent the breadth of the health and medicines ecosystem, from research, clinical development and manufacturing, through to patient charities, research policy organisations and academic institutions. This means EMIG has become a platform for greater knowledge and ideas exchange.

EMIG Members List


Academy of Medical Sciences
Accord Healthcare
Action Duchenne
Action on Hearing Loss
Addex Therapeutics
Aegerion Pharma
Akcea Therapeutics
Alexion Pharmaceuticals
Alison Campbell Associates
Alkaptonuria Society
Allergan Ltd
Alliance Pharma plc
Altacor Pharma Ltd
Amryt Pharma
Amyloidosis Research Consortium
Andrew Carr Associates
ApoPharma Inc
Applied Driving Techniques
Aquila Biolabs
Ashfield Healthcare
Aspire Pharma
Association of Medical Research Charities
Avitus Group
Axis Healthcare Consulting


Besins Healthcare
Bham Pharma Ltd
BGP Products Ltd (Mylan)
Bial Pharma
BioCryst Pharmaceuticals
Biotherapy Services Ltd
Birmingham Health Partners
Boom! Healthcare Communications
British Liver Trust
Business France


C3 Collaborating for Health
C&D Data
Cambridge Enterprise
Cambridge Healthcare
Cambridge Rare Disease Network
Cancer Research UK
Chapper Healthcare
Charlwood Pharma
Chiesi Pharmaceuticals
Costello Medical
Consilient Health
CSL Behring
Curium Pharma
Custom Healthcare
Cystic Fibrosis Trust


Daiichi Sankyo
Daniel and Daisy Novel Therapeutics Ltd
Davies Consulting
Dee Pharmaceuticals Ltd
Dermal Laboratories Ltd
Desitin Pharma
Diabetes Professional Care
Dierks & Company
Draper & Dash
Dr Falk Pharma UK Ltd


Equa Pharma Ltd
ESMS Global – Emergency Scientific & Medical Services
European Association for Logistics and Transportation in Healthcare
European Confederation of Pharmaceutical Entrepreneurs
EUSA Pharma
Everything Genetic
Experimental Cancer Medicine Centres


Fendix Media
Ferring Pharmaceuticals Ltd
Fight for Sight
Fish Pharma Recruitment
Flexipharm Austrading
Flynn Pharma
Four Public Affairs
FTI Consulting
Funding Neuro


Galderma (UK) Ltd
Gedeon Richter
Genetic Alliance
Genetic Disorders UK
Genomics England
Gilead Sciences Int ltd
Grifols UK Ltd
Guerbet Laboratories
GW Pharmaceuticals


Hansa Biopharma
Havas M&C
Healthcare at Home
Health House
Healthcare Business Managers Group
HFA Healthcare Products Ltd
Horizon Pharma
HRA Pharma Ltd


ICL Therapeutics
Imperial College London
Intercept Pharmaceuticals
International Health Partners
International Gaucher Alliance
Intrapharm Laboratories
IQ Pharma


Jazz Pharmaceuticals
Jenson R+


Kidney Research UK
King’s Health Partners
Kowa Research Europe Ltd
Kyowa Kirin


Leadiant Biosciences
Leicester School of Pharmacy, De Montfort University
Leukaemia CARE
LFB Biopharmaceuticals
Lipodystrophy UK
Logixx Pharma Ltd
Lucane Pharma SA


Map BioPharma
MaimoniDex RA Ltd/MaimoniDex (UK) Ltd
Medical Need Europe
Medical Research Council Technology
Merz Pharma Ltd
Metabolic Support UK
Moorfields Pharmaceuticals
MORPh Consultancy Ltd
MPS Society
Muscular Dystrophy Campaign
Myeloma UK
My Name’5 Doddie Foundation


National Clinical Homecare Association

NHS Confederation
National Services for Health Improvement
National Voices
Neimann-Pick UK
Network Pharma
NHS Alliance
Nordic Pharma
Novo Nordisk
Novartis Gene Therapies


Open Health
Orphan Insight Ltd
Oxygen Strategy


ParaPharm Development
Patients Direct
Pharma Solutions
Pharmaceutical Marketing Society
Pharmiweb Solutions
Pierre Fabre
Pinsent Masons
Polycystic Kidney Disease Charity
Plymouth University
Pompe Support Network
Precision Medicine Catapult
Present Value Ltd


Queen Mary University of London


Rare Disease UK
Rarer Cancers Foundation
Rare Revolution Magazine
Real Regulatory
Ridge Pharma
Roboleo & Co
Roche Diabetes Care
Rocket Science Consultancy
Royal Society of Biology


Santhera Pharmaceuticals
Sanofi Genzyme
Servier Laboratories Ltd
Sigma-Tau Pharmaceuticals
Spark Health
Spirit Healthcare
Star Medical
Stirling Anglian Pharmaceuticals
Structural Genomics Consortium, Oxford University
Swedish Orphan Biovitrum Ltd


Tanner Pharma
Techdow Pharma
Teijin Pharma
Tetris Pharma
The Alkaptonuria Society
The Healthcare Partnership
The Institute of Cancer Research
The M.E. Trust
Thea Pharmaceuticals
The Medical Research Network
The Royal Osteoporosis Society
The Urology Company Ltd
Thornton & Ross Pharmaceuticals
Tillotts Pharma (UK) Ltd


UCL Business
UCL Partners
UK Innovation Forum
Universities UK
University of Bristol
University of Exeter
University of Leicester
University of Manchester
University of Southampton, Research & Innovation Services
University of Wolverhampton


V Pharma
Veale Wasbrough Vizards
Vidant Pharma
Vifor Pharma


Wave Data Ltd
WEP Clinical
Whately-Smith Ltd
Wilmington Healthcare




Zebra26 Ltd

What We Do

EMIG enables members to network and meet like-minded professionals who experience the same industry challenges

David Bloomfield

All our Special Interest Groups meet three times a year in central London and any member is entitled to join.

Darren Spevick

EMIG represents its Members on the issues directly affecting their businesses.

Leslie Galloway

How we work

EMIG Steering Group
  • The Steering Group oversees the operation of the organisation, its priorities and work programme, and is led by Leslie Galloway. We are unique among life sciences trade associations in that we have a patient organisation representative on the Group.
  • Members of the EMIG Steering Group include our Chairman, Leslie Galloway, Vice Chairman, Abid Karim, Legal Advisor Paul Ranson, Eric Low, who started Myeloma UK, and now contributes to patient access to medicines via Eric Low Consulting, and 12 heads of Member Companies.
  • Our policy is ‘One Member – One Vote’. This means our work programme can be developed and approved by the full breadth of our Membership, with full transparency.









EMIG Projects & Collaborations

  • EMIG is committed to collaborative working with academia, charities, patient groups and research-focused bodies to encourage scientific research and innovation in the UK. Better Research for Better Outcomes is an initiative joining up stakeholders from these communities to lead a work programme that seeks to develop a UK value framework for better research.
  • Through EMIG’s Medical Directors Forum, we enable all types of Member organisations to work for collaborative advantage, to encourage the sharing of pre-competitive data and best practices, and to ensure that knowledge, innovation and enterprise can be effectively curated with the life sciences sector in the UK.
  • EMIG works alongside our trade association colleagues in life sciences on shared issues.
Special Interest Groups
We have a number of SIGs to reflect the differing priorities and needs of the myriad roles that make a successful biopharmaceutical company. SIGs meet quarterly and inform EMIG positions on a wide range of issues, from regulation and research, to pricing and orphan diseases.
Each Group has a Chair and the Group determines the content of each meeting agenda.
All our SIGs meet quarterly, mostly in central London, and any Member is entitled to join. Policy proposals made by the SIGs are reviewed by the EMIG Steering Group, and ratified by the Membership, often at our Quarterly Meetings throughout the year.
See how our Special Interest Groups can benefit you:
EMIG has the following Special Interest Groups:
Business Development

The EMIG Business Development Group is a networking meeting for those members focussed on building their business by M&A, licensing, partnering and novel in market strategies.

The Group meets quarterly at the Manor, Weston on the Green, Oxfordshire. Every meeting starts with a networking lunch followed by an afternoon of interesting content which might typically include:

  • a member company showcasing their business and strategy
  • case histories of deals completed
  • contemporary topics affecting the marketplace
  • professional advice & services from member companies.

The meeting is followed by a networking dinner.

The Group was established in 2010 and has become a firm fixture on the UK business development calendar.






The EMIG Digital Health Group is a networking meeting for those members focused on understanding the latest developments in digital health and going “beyond the pill”.  

The Group meets 3 times a year, typically in London. Every meeting starts with a networking coffee followed by a few hours of interesting content which might typically include presentations by:

  • members on what they are doing in digital health
  • digital health companies
  • other relevant stakeholders e.g., NHS Digital, digitalhealth.london, MHRA etc.


The Finance Group meets on a quarterly basis to learn, debate and help shape the critical topics and issues affecting the industry from a finance perspective.

The Finance Group is focussed on offering members an opportunity to:

  • network and meet like-minded professionals who experience the same industry challenges
  • gain knowledge and learn, with presentations and talks that are focussed on the finance community’s needs’
  • have a sounding board for practical issues and give support to others
  • share experiences and explore different approaches.

The EMIG HR Group meets four times per year in London and provides a great opportunity for HR professionals to come together for networking and the exchange and sharing of information and new ideas.

We regularly feature external speakers and Members have the opportunity to agree topics to be explored at future meetings. We also offer Members the opportunity to:

  • gain knowledge and learn, with presentations and talks that are focussed on Members’ needs
  • network and meet like-minded professionals who experience the same industry challenges
  • debate important topics
  • provide a sounding board for practical issues and give support to others.

Current issues being looked at by the Group include pricing and reimbursement transparency, data protection, medical devices approval and safety, biosimilars and rare diseases. This is in addition to other changes that impact on companies more widely such as competition law, bribery and corruption, tax and patents and other intellectual property.

So that EMIG members can keep up to date with changes that most affect their business Pinsent Masons LLP and Alexander Natz, Secretary-General of EUCOPE have agreed to establish and run a quarterly EU and Legal Issues Special Interest Group. The aim will be to review recent and forthcoming changes and discuss in depth issues where Government consultation is ongoing or where urgent action may be necessary.

Meetings will be held at Pinsent Masons’ offices in the City. Further details including the agenda will be sent out by way of a reminder nearer the time.

Market Access

The Market Access Group aims to:

  • reduce the hurdles to uptake in the UK and enable innovative products to reach patients in a timely manner

  • identify cost-effective solutions to market access challenges

  • work with government and officials to communicate new developments

  • understand the impact on the varied range of EMIG member companies (biotechs to mature companies) of gaining market access in the UK.

Medical Directors’ Forum

The EMIG Medical Directors’ Forum aims:

  • to promote a scientific and medical research policy and operating environment that supports the growth and sustainability of small to medium-sized pharmaceutical companies

  • to identify and access new partnership opportunities for technology development with academia and the NHS

  • to build an innovative open platform for knowledge exchange and collaboration between diverse life sciences organisations.

EU and Legal Issues Group

So that EMIG members can keep up to date with changes that most affect their business Pinsent Masons LLP and Alexander Natz, Secretary-General of EUCOPE run a quarterly EU and Legal Issues Special Interest Group. The aim is to review recent and forthcoming changes and discuss in depth issues where Government consultation is ongoing or where urgent action may be necessary.


The EMIG Regulatory Group holds regular information sharing and networking meetings for those members working in Regulatory Affairs, related disciplines or those with an interest in understanding more about current challenges impacting the industry.

The Group meets at least three time a year in London. Each meeting focuses on current hot topics and takes the form of presentations and/or group discussions. External experts and Regulatory Authority personnel are often invited as appropriate. Events are a valuable networking opportunity, with time allocated at the start of each session for informal networking.

In addition, the EMIG Regulatory Group takes the lead on two key MHRA meetings for our membership:

  • cross trade meeting
  • bi-lateral meeting.
EMIG Northern Ireland Group

The Northern Ireland Group provide a platform for engagement with the NHS and other stakeholders in Northern Ireland and enable networking and shared learning across Member companies.

A political update is presented at each meeting.

EMIG Scotland Group

The EMIG Scotland Group focuses on issues including:

  • co-operation with the Scottish Lifesciences Association

  • engagement with SMC

  • SMC position on uptake and clinical standards

  • CEL 17 and the question of how it needs to be implemented by Health Boards.

EMIG Wales Group

The EMIG Wales Group was established to:

  • provide a voice for members in Wales

  • build relations with the All Wales Medicines Strategy Group and with key stakeholders in the Welsh Assembly

  • engage with Bioinnovation Wales.

EMIG’s mission

“We work closely with government, regulators, HTA bodies, academia, medical research organisations and the NHS to advance patient access to the most effective and innovative medicines; to promote the UK as an attractive environment for research and investment; and to enhance our Members’ ability to operate effectively.”










Our Values

In pursuing our mission we strive to be:

  • Patient-centred

  • Accountable

  • Results focused

  • Collaborative

  • Innovative

  • Evidence-based

  • Open